Tirzepatide for MASH/NAFLD: A Potential Game-Changer for Liver Disease

Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH) affects millions worldwide and has no widely approved pharmacological treatment. Tirzepatide is emerging as a potential breakthrough.

The SYNERGY-NASH Trial

This Phase 2 trial evaluated tirzepatide in patients with biopsy-confirmed MASH:

Key Results

• MASH resolution without worsening fibrosis: Achieved in up to 74% of patients on the highest dose (vs. 13% placebo)
• Fibrosis improvement: Up to 59% of patients showed improvement (vs. 25% placebo)
• Liver fat reduction: Dramatic reductions in hepatic fat content measured by MRI

Study Details

• 190 patients with biopsy-confirmed MASH (fibrosis stages F1-F3)
• Treatment duration: 52 weeks
• Doses: 5 mg, 10 mg, 15 mg weekly

Why Tirzepatide Works for Liver Disease

Direct Mechanisms

• GIP receptor activation improves hepatic fat metabolism
• GLP-1 receptor signaling reduces hepatic glucose production
• Dual agonism enhances mitochondrial function in hepatocytes

Indirect Mechanisms

• Significant weight loss reduces fat delivery to the liver
• Improved insulin sensitivity reduces de novo lipogenesis
• Reduced inflammation systemically and within the liver
• Improved adipokine profile reduces hepatic inflammation

The Scope of the Problem

• MASLD (fatty liver disease) affects ~25% of the global population
• MASH affects ~5% globally (~16 million Americans)
• MASH can progress to cirrhosis, liver failure, and hepatocellular carcinoma
• Currently the leading indication for liver transplantation in women

Future Directions

Eli Lilly has initiated Phase 3 trials (SYNERGY) for tirzepatide in MASH. If successful, this could become the third FDA-approved indication for tirzepatide, addressing a massive unmet medical need.